Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer

摘要: Abstract Objective Not all patients with relapsed ovarian cancer (EOC) benefit from further treatment and thus should be selectively applied. Methods/patients A retrospective review of survival response outcomes in 120 women EOC, treated at original diagnosis surgery platin plus paclitaxel, who had their initial subsequent relapse therapy carried out the BCCA. Results In those selected for re-treatment upon relapse, lack progression rates were 63%, 50%, 45%, 44%, 29%, 20% respectively first through sixth relapse. The corresponding median survivals that 14, 10, 6, 7, 8, 5 months. predictive model based length interval between two preceding relapses (or to 2nd relapse) predicted which would survive less than 6 months (patient defined "lack benefit" chemotherapy criterion): second Conclusion patients, multiple episodes are value. time-based statistic identifies will not benefit, as